ACM
CELGZ

Ayer Capital Management’s Celgene Corporation Contingent Value Rights CELGZ Stock Holding History

Ayer Capital Management’s Portfolio CELGZ Stock Details CELGZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-1,399,919
Closed -$11.2M – 2
2013
Q3 		$11.2M Sell
1,399,919
-347,456
-20% -$2.68M 61.08% 1
2013
Q2 		$12.9M Buy
+1,747,375
New +$12.7M 76.53% 1

Other funds holding CELGZ

OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
FA
FCG Advisors Chatham, New Jersey $425M AUM 12.09% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
U
UBS Zurich, Switzerland $136B AUM 16.36% 1-Year Est. Return

Ayer Capital Management's CELGZ Position: Q4 2013 in Review

Ayer Capital Management sold out of Celgene Corporation Contingent Value Rights (CELGZ) in Q4 2013, closing a stake of 1,399,919 shares — an estimated $11.2M sold.

Ayer Capital Management first reported a position in CELGZ in Q2 2013 and held it in 2 quarters. The position peaked at $12.9M in Q2 2013. 25 funds tracked by Wall St. Rank hold CELGZ as of Q4 2013.

  • Ayer Capital Management reported no remaining Celgene Corporation Contingent Value Rights position as of Q4 2013 after selling out during the quarter.
  • Ayer Capital Management sold 1,399,919 Celgene Corporation Contingent Value Rights shares in Q4 2013, an estimated $11.2M.
  • Ayer Capital Management first reported a position in Celgene Corporation Contingent Value Rights in Q2 2013 and held it in 2 quarters.
  • Ayer Capital Management's Celgene Corporation Contingent Value Rights position peaked at $12.9M in Q2 2013.
  • 25 funds tracked by Wall St. Rank held Celgene Corporation Contingent Value Rights as of Q4 2013.

Based on Ayer Capital Management's 13F filing for Q4 2013, filed 18 Feb 2014.